 Ritsuko Iwanaga
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| E2F1 Transcription Factor | 14 | 2026 | 72 | 2.010 |
Why?
| | E2F Transcription Factors | 8 | 2026 | 79 | 0.930 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2026 | 1487 | 0.920 |
Why?
| | Promoter Regions, Genetic | 14 | 2026 | 1263 | 0.730 |
Why?
| | Genes, Tumor Suppressor | 6 | 2026 | 92 | 0.700 |
Why?
| | Gene Products, tax | 3 | 2025 | 15 | 0.670 |
Why?
| | Human T-lymphotropic virus 1 | 3 | 2025 | 32 | 0.660 |
Why?
| | Positive Regulatory Domain I-Binding Factor 1 | 1 | 2020 | 17 | 0.650 |
Why?
| | Melanocytes | 1 | 2020 | 66 | 0.630 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 732 | 0.620 |
Why?
| | Zebrafish Proteins | 1 | 2020 | 298 | 0.520 |
Why?
| | Transcriptional Activation | 5 | 2025 | 380 | 0.500 |
Why?
| | Ovarian Neoplasms | 4 | 2024 | 586 | 0.470 |
Why?
| | Zebrafish | 1 | 2020 | 510 | 0.470 |
Why?
| | Ligaments | 1 | 2016 | 74 | 0.460 |
Why?
| | Cell Line, Tumor | 15 | 2026 | 3611 | 0.460 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 894 | 0.450 |
Why?
| | Pelvis | 1 | 2016 | 121 | 0.450 |
Why?
| | Uterus | 1 | 2016 | 221 | 0.440 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2024 | 539 | 0.430 |
Why?
| | DEAD-box RNA Helicases | 2 | 2025 | 90 | 0.430 |
Why?
| | Models, Animal | 1 | 2016 | 392 | 0.420 |
Why?
| | Vagina | 1 | 2016 | 193 | 0.420 |
Why?
| | Homeodomain Proteins | 3 | 2012 | 523 | 0.410 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2024 | 60 | 0.400 |
Why?
| | Retinoblastoma Protein | 6 | 2026 | 109 | 0.390 |
Why?
| | Melanoma | 1 | 2020 | 807 | 0.390 |
Why?
| | Histone-Lysine N-Methyltransferase | 2 | 2024 | 141 | 0.370 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 484 | 0.370 |
Why?
| | Gene Expression Regulation | 6 | 2023 | 2621 | 0.360 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 177 | 0.350 |
Why?
| | Tumor Protein p73 | 3 | 2026 | 18 | 0.320 |
Why?
| | Neoplastic Stem Cells | 3 | 2014 | 414 | 0.310 |
Why?
| | Neoplasms | 5 | 2026 | 2804 | 0.300 |
Why?
| | Cyclin-Dependent Kinases | 3 | 2026 | 147 | 0.260 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2025 | 17 | 0.240 |
Why?
| | Mouse Embryonic Stem Cells | 1 | 2026 | 40 | 0.240 |
Why?
| | HTLV-I Infections | 1 | 2025 | 28 | 0.240 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 134 | 0.230 |
Why?
| | Breast Neoplasms | 3 | 2014 | 2318 | 0.230 |
Why?
| | Growth Substances | 1 | 2004 | 140 | 0.220 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2024 | 25 | 0.210 |
Why?
| | BRCA2 Protein | 1 | 2024 | 64 | 0.210 |
Why?
| | Mice | 9 | 2026 | 18378 | 0.200 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2024 | 84 | 0.200 |
Why?
| | Animals | 12 | 2026 | 38010 | 0.200 |
Why?
| | Fibroblasts | 5 | 2018 | 1044 | 0.190 |
Why?
| | Transcription Factor DP1 | 2 | 2023 | 26 | 0.190 |
Why?
| | Signal Transduction | 4 | 2025 | 5214 | 0.180 |
Why?
| | DNA Repair | 1 | 2004 | 250 | 0.180 |
Why?
| | Apoptosis | 9 | 2026 | 2519 | 0.180 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2024 | 875 | 0.180 |
Why?
| | Cell Proliferation | 6 | 2026 | 2542 | 0.170 |
Why?
| | Tumor Suppressor Protein p14ARF | 2 | 2014 | 7 | 0.170 |
Why?
| | Tumor Suppressor Proteins | 2 | 2014 | 330 | 0.170 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2016 | 16 | 0.160 |
Why?
| | Bcl-2-Like Protein 11 | 2 | 2016 | 38 | 0.160 |
Why?
| | Humans | 28 | 2026 | 143560 | 0.160 |
Why?
| | Prognosis | 3 | 2020 | 4152 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 928 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 2 | 2015 | 626 | 0.130 |
Why?
| | Genes, p16 | 1 | 2016 | 14 | 0.130 |
Why?
| | Macrophages | 1 | 2024 | 1506 | 0.120 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 127 | 0.120 |
Why?
| | Connective Tissue | 1 | 2016 | 38 | 0.120 |
Why?
| | Cell Cycle Proteins | 4 | 2023 | 651 | 0.120 |
Why?
| | DNA-Binding Proteins | 4 | 2018 | 1524 | 0.120 |
Why?
| | Survival Rate | 1 | 2020 | 2003 | 0.120 |
Why?
| | Pelvic Organ Prolapse | 1 | 2016 | 59 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2016 | 151 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2014 | 16 | 0.110 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2015 | 188 | 0.110 |
Why?
| | Disease Progression | 2 | 2020 | 2856 | 0.110 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 374 | 0.110 |
Why?
| | Transcription Factors, TFII | 2 | 2024 | 44 | 0.110 |
Why?
| | Nuclear Proteins | 2 | 2012 | 749 | 0.100 |
Why?
| | Neoplasms, Experimental | 1 | 2014 | 174 | 0.100 |
Why?
| | Cells, Cultured | 1 | 2020 | 4182 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2014 | 346 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2020 | 2020 | 0.090 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 33 | 0.090 |
Why?
| | Heterografts | 1 | 2012 | 138 | 0.090 |
Why?
| | Cell Line | 4 | 2018 | 2897 | 0.090 |
Why?
| | Female | 8 | 2024 | 77251 | 0.080 |
Why?
| | NF-kappa B | 2 | 2025 | 685 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2012 | 526 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 1 | 2016 | 2531 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2015 | 1171 | 0.070 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2008 | 79 | 0.070 |
Why?
| | Response Elements | 2 | 2008 | 89 | 0.070 |
Why?
| | Protein Binding | 4 | 2024 | 2261 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4522 | 0.070 |
Why?
| | Rats | 1 | 2016 | 5610 | 0.070 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2016 | 90 | 0.060 |
Why?
| | MutS Homolog 3 Protein | 1 | 2004 | 2 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1794 | 0.060 |
Why?
| | Acid Anhydride Hydrolases | 1 | 2004 | 6 | 0.060 |
Why?
| | MutL Protein Homolog 1 | 1 | 2004 | 9 | 0.060 |
Why?
| | MutS Homolog 2 Protein | 1 | 2004 | 13 | 0.060 |
Why?
| | Culture Media, Serum-Free | 1 | 2004 | 45 | 0.060 |
Why?
| | Rad51 Recombinase | 1 | 2004 | 15 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 6043 | 0.060 |
Why?
| | DNA Repair Enzymes | 1 | 2004 | 29 | 0.050 |
Why?
| | Cyclin D2 | 1 | 2024 | 5 | 0.050 |
Why?
| | Base Sequence | 2 | 2005 | 2199 | 0.050 |
Why?
| | Jurkat Cells | 1 | 2024 | 118 | 0.050 |
Why?
| | Histocompatibility Antigens | 1 | 2024 | 108 | 0.050 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2024 | 80 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2024 | 51 | 0.050 |
Why?
| | Mice, Nude | 1 | 2025 | 710 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2005 | 273 | 0.050 |
Why?
| | E2F3 Transcription Factor | 1 | 2023 | 10 | 0.050 |
Why?
| | Transcription Factors | 2 | 2018 | 1754 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2005 | 451 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 2005 | 2942 | 0.050 |
Why?
| | Polycomb-Group Proteins | 1 | 2023 | 35 | 0.050 |
Why?
| | Cell Death | 1 | 2024 | 394 | 0.050 |
Why?
| | Cell Division | 1 | 2004 | 806 | 0.050 |
Why?
| | Protein Domains | 1 | 2024 | 308 | 0.050 |
Why?
| | DNA Replication | 1 | 2004 | 251 | 0.050 |
Why?
| | Telomerase | 1 | 2005 | 249 | 0.050 |
Why?
| | Neoplasm Transplantation | 2 | 2014 | 253 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2004 | 441 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2004 | 443 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2580 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2024 | 941 | 0.040 |
Why?
| | Lysine | 1 | 2023 | 301 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2004 | 752 | 0.040 |
Why?
| | Serum | 2 | 2012 | 58 | 0.040 |
Why?
| | Transplantation, Heterologous | 2 | 2012 | 197 | 0.040 |
Why?
| | Mice, SCID | 2 | 2012 | 372 | 0.040 |
Why?
| | Phosphorylation | 1 | 2024 | 1781 | 0.040 |
Why?
| | Adenovirus E1A Proteins | 2 | 2012 | 15 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 686 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2005 | 1511 | 0.040 |
Why?
| | Histones | 1 | 2024 | 666 | 0.040 |
Why?
| | ADP-Ribosylation Factors | 1 | 2018 | 18 | 0.040 |
Why?
| | Dimerization | 1 | 2018 | 197 | 0.030 |
Why?
| | Peptides | 1 | 2023 | 976 | 0.030 |
Why?
| | Ectopic Gene Expression | 1 | 2016 | 5 | 0.030 |
Why?
| | RNA Interference | 1 | 2018 | 474 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2005 | 2026 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 637 | 0.030 |
Why?
| | Claudins | 1 | 2014 | 24 | 0.030 |
Why?
| | Genes, Transgenic, Suicide | 1 | 2014 | 7 | 0.030 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2014 | 100 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 336 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2014 | 720 | 0.020 |
Why?
| | Genetic Therapy | 1 | 2014 | 319 | 0.020 |
Why?
| | Culture Media | 1 | 2012 | 165 | 0.020 |
Why?
| | Etoposide | 1 | 2012 | 165 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2012 | 185 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2014 | 1272 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2014 | 642 | 0.020 |
Why?
| | Adenoviridae | 1 | 2012 | 204 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2012 | 382 | 0.020 |
Why?
| | Point Mutation | 1 | 2012 | 243 | 0.020 |
Why?
| | Antioxidants | 1 | 2014 | 594 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2012 | 2852 | 0.020 |
Why?
| | Transfection | 1 | 2012 | 949 | 0.020 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2009 | 68 | 0.020 |
Why?
| | E2F4 Transcription Factor | 1 | 2008 | 8 | 0.020 |
Why?
| | Mesoderm | 1 | 2009 | 147 | 0.020 |
Why?
| | Epithelium | 1 | 2009 | 314 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1192 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1736 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2014 | 1370 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 607 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 682 | 0.020 |
Why?
| | Cyclin D | 1 | 2005 | 11 | 0.010 |
Why?
| | Cyclin D1 | 1 | 2005 | 74 | 0.010 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2005 | 88 | 0.010 |
Why?
| | Cyclins | 1 | 2005 | 101 | 0.010 |
Why?
| | Gene Silencing | 1 | 2005 | 201 | 0.010 |
Why?
| | Gene Expression | 1 | 2009 | 1505 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2009 | 2194 | 0.010 |
Why?
| | Binding Sites | 1 | 2005 | 1325 | 0.010 |
Why?
| | Cell Cycle | 1 | 2005 | 648 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 863 | 0.010 |
Why?
| | Models, Biological | 1 | 2005 | 1831 | 0.010 |
Why?
| | Mutation | 1 | 2005 | 4053 | 0.010 |
Why?
| | Male | 1 | 2009 | 71500 | 0.000 |
Why?
|
|
Iwanaga's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|